Prices for Indian consumers are expected to come down significantly from the current Rs 17,000-Rs 26,000 monthly.

A new daily pill for obesity, orforglipron, has shown promising results in a major clinical trial, helping patients lose ...

Researchers at Syracuse University have identified a brain peptide, TDN, that effectively curbs appetite and enhances glucose ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the National Pharmacy Association.

Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to 10–16% (from 16-24%) and revenue growth projections to 8-14% (from 13-21%) at ...

Peter Kyle said he wants the likes of Wegovy and Mounjaro to be 'widely used' and made 'available to everyone from every background'.

If you’re pregnant or hoping to become pregnant, it’s natural to have questions about your medications. And if you’re taking ...

Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...

Two of the world's most popular slimming injections may raise the risk of a sight-threatening eye disease in people with type ...

Novo Nordisk A/S is suffering from headwinds in its core anti-obesity medications market. Click here to find out why NVO ...

In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

Novo Nordisk's legal actions against U.S. pharmacies over compounded copies of its drug Wegovy exclude Hims & Hers, a ...